Contact Us
Drug Search Results
More Filters [+]

Squalamine

Alternative Names: squalamine
Latest Update: 2024-01-10
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: Angiogenesis Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral,Ophthalmic

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Genaera
Company Location: PLYMOUTH MEETING PA 19462
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Squalamine

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Wet Macular Degeneration|Choroidal Neovascularization|Macular Degeneration

Phase 2: Retinal Neovascularization|Choroidal Neovascularization|Diabetic Retinopathy|Ovarian Cancer|Macular Degeneration|Wet Macular Degeneration|Retinal Vein Occlusion|Macular Edema|Prostate Cancer

Phase 1: Amyotrophic Lateral Sclerosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
ACTRN12619000375156

P1

Completed

Amyotrophic Lateral Sclerosis

2018-11-06

MAKO

P3

Unknown status

Macular Degeneration

2017-12-01

OHR-1501

P2

Withdrawn

Wet Macular Degeneration

2016-04-01

Ohr-005

P2

Withdrawn

Macular Edema|Diabetic Retinopathy

2015-09-01

Recent News Events

Date

Type

Title

01/10/2024

PubMed

 Squalamine reverses age-associated changes of firing patterns of myenteric sensory neurons and vagal fibres.

12/20/2023

PubMed

 Antibiofilm and Antivirulence Properties of 6-Polyaminosteroid Derivatives against Antibiotic-Resistant Bacteria.

11/13/2023

PubMed

 Ceragenins and Ceragenin-Based Core-Shell Nanosystems as New Antibacterial Agents against Gram-Negative Rods Causing Nosocomial Infections.

05/31/2023

News Article

 Enterin announces FDA acceptance of an investigator sponsored IND to treat a patient with prodromal multisystem atrophy (MSA) with ENT-01

11/19/2021

News Article

 Enterin Announces That the Enteric Nervous System Directly Impacts Neuropsychiatric Symptoms

11/19/2021

News Article

 Enterin Announces Publication of Exciting Discoveries About the Enterin Nervous System

11/19/2021

News Article

 Enterin Announces Publication of Exciting Discoveries About the Enteric Nervous System

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions